Beringea U.S. portfolio company Flywheel, the leading medical imaging data and AI platform, has raised $54 million in Series D funding. This latest round was co-led by Novalis LifeSciences LLC and NVentures, NVIDIA’s venture capital arm. Microsoft also participated in the round, along with Beringea and other returning investors.
The funding will fuel Flywheel’s continued growth in its two primary markets (public sector healthcare and pharmaceutical companies) while accelerating expansion in other markets, including providers, payers, system integrators, and software companies seeking to harness the value of their data for AI development. The capital infusion will also help Flywheel extend its global reach into key geographies, particularly across Europe.
“Flywheel’s products transform healthcare innovation by empowering organizations to efficiently and securely ingest, curate and share medical imaging data for accelerated research and AI development,” said Flywheel CEO Jim Olson.
“Beringea is excited to partner with leading growth capital providers and innovative strategic partners to further foster Flywheel’s growth and advance the use of AI to bring efficiency to healthcare development processes,” said William Blake III, partner at Beringea and board director at Flywheel.
Flywheel is the pioneering medical imaging data and AI platform powering healthcare innovation through streamlined medical imaging data management, curation and analysis. Flywheel helps organizations turn complex imaging data into analysis-ready datasets for accelerated research
and AI development. Flywheel offers comprehensive solutions for pharma companies, providers, payers, system integrators, AI developers and academic medical centers to get optimum value out of their data assets. Flywheel is an Invenshure-founded company headquartered in Minneapolis, with offices in the Bay Area, St. Louis, and Budapest. For more information on our mission and products, visit www.flywheel.io or follow us on Twitter and LinkedIn.